Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Human Cell Line Produces High-Quality RSV for Vaccine Production

By BiotechDaily International staff writers
Posted on 23 Mar 2014
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Image: Electron micrograph reveals the morphologic traits of the respiratory syncytial virus (RSV). The virion is variable in shape, and size (average diameter of between 120–300 nm). RSV is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
Cooperation between German and American biotechnology companies may pave the way for development of a vaccine to prevent RSV (respiratory syncytial virus) respiratory infections, which have been estimated to cause nearly 7% of the deaths of infants that die during their first year of life.

The companies involved are CEVEC Pharmaceuticals (Cologne, Germany), a clinical stage pharmaceutical company focusing on the development of highly potent protein and vaccine expression systems based on human CAP cells and Paragon Bioservices Inc. (Baltimore, MD, USA), a leading American biopharmaceutical contract manufacturer.

CEVEC has developed a new and proprietary expression system for biopharmaceuticals offering significant advantages over existing production technologies. Their CAP cells are an immortalized cell line derived from primary human amniocytes that meet the highest ethical and regulatory standards. CEVEC´s CAP cells have proven highly efficient in the production of a broad range of otherwise difficult to express glycoproteins. These molecules are produced at high titers with authentic post-translational modifications in serum-free suspension culture. Their ability to generate human glycosylation patterns also makes CAP cells a valuable tool for vaccine production.

The CEVEC/Paragon project has succeeded in producing RSV in CAP cells that show a high-level of functional G-protein resulting in a very effective RSV vaccine with positive impact on attenuated-vaccine studies.

"Again CAP cells prove their enormous potential and significant advantages over many currently used production systems for vaccines," said Dr. Rainer Lichtenberger, COO of CEVEC. "Next to Cytomegalovirus, influenza, and others, this is another striking example that CAP cells can efficiently propagate disease relevant human viruses. We were very pleased to work with Paragon on this project and benefited from their experience in vaccine production. This collaboration was extremely pleasant and successful."

Marco Chacón, CEO of Paragon said, "This teamwork pays not only for CEVEC, but also for Paragon. With use of CAP cells we can offer our customers a unique production system to meet the challenges of their vaccine target. With this highly ambitious project we have again proven our expertise in this competitive business."

Related Links:

CEVEC Pharmaceuticals
Paragon Bioservices Inc.



SLAS - Society for Laboratory Automation and Screening
RANDOX LABORATORIES
BIOSIGMA S.R.L.
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: The Human Protein Atlas is tissue-based map of the human proteome (Photo courtesy of the Human Protein Atlas).

Open Source Tissue-Based Map of the Human Proteome Launched

Constructed with 13 million annotated images, an interactive database has been created to show the distribution of proteins in all major tissues and organs of the human body. Ten years after the completion... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.